Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Emerging Markets R&D Head RuiPing Dong On Developing Drugs To Meet Local Needs: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Merck discusses its R&D strategy in emerging markets; the company announced last week the largest ever R&D investment in China for a pharmaceutical company.


Related Content

Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
Merck Invests In China Oncology Start-up BeiGene
Merck Teams Up With Sinopharm On Vaccines As It Gears Up For Gardasil Approval In China


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts